Showing results (91-100 of 98) with videos related to
Sort By:
Pageof 10
You have reached the last page of results.This site can display upto 98 results.
European Journal of Cancer (Oxford, England : 1990)|February 17, 2026
Ten-year overall survival in resectable stage-III NSCLC - Results of the randomized ESPATUE trial - Long-term survival and competing risk analysisWilfried Ernst Erich Eberhardt, Christina Schulte, Christoph Pöttgen, et al.European Journal of Cancer (Oxford, England : 1990)|February 20, 2024
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in GermanyJan A Stratmann, Friederike C Althoff, Paula Doebel, et al.Nature Communications|January 12, 2018
Integrative genomic and transcriptomic analysis of leiomyosarcomaPriya Chudasama, Sadaf S Mughal, Mathijs A Sanders, et al.The Lancet. Oncology|October 26, 2016
Histopathological regression after neoadjuvant docetaxel, oxaliplatin, fluorouracil, and leucovorin versus epirubicin, cisplatin, and fluorouracil or capecitabine in patients with resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4-AIO): results from the phase 2 part of a multicentre, open-label, randomised phase 2/3 trialSalah-Eddin Al-Batran, Ralf D Hofheinz, Claudia Pauligk, et al.JCO Precision Oncology|February 9, 2022
Validating Comprehensive Next-Generation Sequencing Results for Precision Oncology: The NCT/DKTK Molecularly Aided Stratification for Tumor Eradication Research ExperienceAmelie Lier, Roland Penzel, Christoph Heining, et al.JCO Precision Oncology|September 11, 2020
Genomic Profiling Identifies Outcome-Relevant Mechanisms of Innate and Acquired Resistance to Third-Generation Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy in Lung CancerSebastian Michels, Carina Heydt, Bianca van Veggel, et al.Lancet (London, England)|April 16, 2019
Perioperative chemotherapy with fluorouracil plus leucovorin, oxaliplatin, and docetaxel versus fluorouracil or capecitabine plus cisplatin and epirubicin for locally advanced, resectable gastric or gastro-oesophageal junction adenocarcinoma (FLOT4): a randomised, phase 2/3 trialSalah-Eddin Al-Batran, Nils Homann, Claudia Pauligk, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 26, 2026
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World CohortOliver Illini, Anna-Carina Hund, Hans-Georg Kopp, et al.Pageof 10